Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
CNY 22.02
(4.61%)
CNY 22.02
(4.61%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 156.12 Million CNY | -103.37% |
| 2022 | 841.8 Million CNY | 51.84% |
| 2021 | 853.11 Million CNY | -15.7% |
| 2020 | 983.88 Million CNY | 2808.82% |
| 2019 | 38.37 Million CNY | 304.13% |
| 2018 | 8.76 Million CNY | 72.83% |
| 2017 | 2.91 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 14.48 Thousand CNY | 130.68% |
| 2024 Q2 | 43.56 Million CNY | 840.29% |
| 2024 Q3 | -986.7 Thousand CNY | -101.59% |
| 2023 Q1 | -28.54 Million CNY | -110.94% |
| 2023 FY | - CNY | -103.37% |
| 2023 Q4 | -21.5 Million CNY | -486.12% |
| 2023 Q3 | 5.57 Million CNY | 116.01% |
| 2023 Q2 | -34.79 Million CNY | -21.9% |
| 2022 Q3 | 174.05 Million CNY | -25.01% |
| 2022 Q2 | 232.08 Million CNY | -56.32% |
| 2022 Q1 | 531.39 Million CNY | 249.37% |
| 2022 FY | - CNY | 51.84% |
| 2022 Q4 | 260.93 Million CNY | 49.92% |
| 2021 Q3 | 195.13 Million CNY | 479.27% |
| 2021 Q1 | 500.71 Million CNY | 99.68% |
| 2021 Q2 | -51.45 Million CNY | -110.28% |
| 2021 FY | - CNY | -15.7% |
| 2021 Q4 | 152.1 Million CNY | -22.05% |
| 2020 Q1 | 195.42 Million CNY | 0.0% |
| 2020 FY | - CNY | 2808.82% |
| 2020 Q3 | 199.51 Million CNY | -40.84% |
| 2020 Q2 | 337.23 Million CNY | 72.56% |
| 2020 Q4 | 250.75 Million CNY | 25.68% |
| 2019 FY | - CNY | 304.13% |
| 2018 FY | - CNY | 72.83% |
| 2017 FY | - CNY | 0.0% |